GLP-1 Fatigue: Why You Feel Tired, and When It Is More Than Tiredness

Start with the primary documents, because they settle the first question quickly. The FDA prescribing information for Wegovy (semaglutide, Novo Nordisk), revised in June 2026, reports adverse reactions from the pooled placebo-controlled trials in adults with obesity or overweight. In that table, fatigue was reported by 11 percent of adults on the once-weekly Wegovy injection and 5 percent of adults on placebo. The footnote says the category includes asthenia, which is the clinical word for a lack of strength or energy. Wegovy's patient Medication Guide lists the same thing in plain language, as tiredness (fatigue), among the most common side effects.

The Zepbound (tirzepatide, Eli Lilly) prescribing information, revised in August 2026, reports fatigue at 5 percent, 6 percent and 7 percent across its three maintenance doses in the pooled weight-reduction trials, against 3 percent on placebo. Its footnote is broader still: asthenia, fatigue, lethargy and malaise are all counted together. So the label figure is not just people who said tired; it includes people who said weak, sluggish or generally unwell.

Mounjaro, the same tirzepatide molecule from Eli Lilly approved for type 2 diabetes, tells a slightly different story. Its August 2026 label lists the adverse reactions that reached 5 percent in the placebo-controlled diabetes trials, and fatigue is not among them; nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain are. But the same label reports that in SURPASS-CVOT, a cardiovascular outcomes trial in adults with type 2 diabetes and established cardiovascular disease, fatigue was reported in 10 percent of the 6,647 adults exposed to Mounjaro. Different population, different trial length, different result.

One caution that every one of these labels prints in its own words: rates observed in the clinical trials of one drug cannot be directly compared with the rates from trials of another drug, and may not reflect what happens in practice. Eleven percent on Wegovy and seven percent on Zepbound are not a ranking; they are two separate answers to whether fatigue is expected, and both are yes, for a minority of people. If you want the broader picture of what else the labels list, our overview of GLP-1 side effects covers the full tables.

The most ordinary cause of GLP-1 fatigue is also the one that is easiest to forget: you are eating substantially less than you were, and in most cases that is the point. Every GLP-1 receptor agonist approved for weight reduction is indicated in combination with a reduced-calorie diet and increased physical activity. That phrase is on the first page of the Wegovy and Zepbound labels. The Zepbound label goes further and describes the lifestyle intervention used in its pivotal trials: instruction on a reduced-calorie diet of approximately 500 kcal per day below maintenance and a recommended minimum of 150 minutes of physical activity a week, starting with the first dose. The Wegovy label describes the same deficit for its trials.

On top of the deliberate deficit sits the drug effect. The Zepbound label states plainly that tirzepatide decreases calorie intake and that the effect is likely mediated by affecting appetite. The Wegovy label's mechanism section describes GLP-1 as a physiological regulator of appetite and caloric intake. Put the two together and a person can end up eating far less than a 500 kcal deficit without noticing, because the hunger that would normally flag it has gone quiet. Running an energy deficit is, by definition, tiring; a larger deficit than intended is more so.

What you eat within that smaller intake matters as much as how much. When appetite is suppressed, the foods that get skipped first are often the ones that take effort: protein, the nutrient most often emphasized for preserving lean mass during weight loss. Our guide to protein on a GLP-1 covers why it matters and how people make room for it on a small appetite.

None of this is a reason to eat past fullness or to change how you take your medication. It is a reason to know your actual intake before deciding the drug is the whole explanation; a week of logged meals often shows whether the tired days and the low-intake days line up.

Dehydration is the second cause worth taking seriously, and the labels take it seriously enough to put it in the warnings. The Wegovy, Zepbound and Mounjaro prescribing information each contain a warning titled Acute Kidney Injury Due to Volume Depletion. The wording is nearly identical across the three: there have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, and the majority occurred in people who had gastrointestinal adverse reactions leading to dehydration, such as nausea, vomiting or diarrhea. The Wegovy Medication Guide translates this for patients: diarrhea, nausea and vomiting may cause a loss of fluids, it is important to drink fluids, and to tell your healthcare provider right away if you have nausea, vomiting or diarrhea that does not go away.

The everyday version is quieter. Many people simply forget to drink when they are not hungry. Mild dehydration feels like tiredness, headache and difficulty concentrating long before it looks like anything medical. Our scenario on how much water to drink on a GLP-1 walks through the practical side, including why the answer is not one universal number.

Sleep is the third cause, and it cuts both ways. In December 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, which is a reminder that many people starting these medications were already sleeping badly for reasons that weight loss can improve over time. In the short term, though, the early weeks can disrupt sleep: nausea in the evening, reflux when lying down, getting up at night to drink or to use the bathroom, and the general strangeness of a changed routine. Poor sleep and low intake compound each other, and it is hard to tell from the inside which one is doing the work.

Alcohol is the fourth. On a smaller appetite and a smaller body, the same drink lands harder, and its effect on sleep quality is something many people notice. Alcohol is also a source of calories that displace food, which on a GLP-1 can mean a glass of wine standing in for dinner. If drinking is part of your week, our scenario on drinking alcohol on a GLP-1 covers what people report and what the labels do and do not say.

For one specific group, fatigue can be a sign of something the labels warn about directly. All three prescribing information documents carry a hypoglycemia warning, and all three single out the same combination. The Wegovy label states that in glycemic control trials the risk of hypoglycemia was increased when semaglutide was used concomitantly with insulin or an insulin secretagogue such as a sulfonylurea, and that patients with diabetes taking Wegovy with either may have an increased risk of hypoglycemia, including severe hypoglycemia. The Mounjaro label says the same of tirzepatide with an insulin secretagogue or insulin. The Zepbound label puts a number on it from its trial in adults with type 2 diabetes: 10.3 percent of Zepbound-treated patients who were also taking a sulfonylurea reported hypoglycemia, compared with 2.1 percent of those not taking one.

Why this belongs on a page about fatigue: the symptoms of low blood sugar are easy to file under tired. The Wegovy Medication Guide lists them as dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, fast heartbeat, headache, jitteriness and weakness. Several of those, on their own, are indistinguishable from a bad night's sleep. Together, and especially with sweating, shakiness or a racing heart, they are a different thing.

The labels also say what to do about the combination, and it is not a patient decision. The Wegovy label advises prescribers to consider reducing the dose of the concomitantly administered insulin or insulin secretagogue when starting treatment, and to monitor blood glucose before and during treatment in people with diabetes. The Mounjaro label says the risk may be lowered by a reduction in the sulfonylurea or insulin dose. Those are instructions to the prescriber. If you take insulin or a sulfonylurea and you are newly tired, dizzy or shaky, the right move is to check your glucose if you have been taught to, and to call the prescriber or pharmacist who manages those medications. Our guide to GLP-1s and type 2 diabetes covers the condition more broadly; how any other diabetes medicine is adjusted alongside a GLP-1 is your prescriber's decision.

If you do not take insulin or a sulfonylurea, the Wegovy label still notes more hypoglycemia on Wegovy than on placebo in patients with type 2 diabetes not on insulin, so it is worth a mention at an appointment. It is a much smaller signal, and the everyday causes above are far more likely.

Much GLP-1 fatigue is ordinary. It tends to be reported in the first weeks and around dose increases; the EU Summary of Product Characteristics for Wegovy, published by the European Medicines Agency, footnotes fatigue in its section 4.8 adverse-reaction table as mainly seen in the dose-escalation period. Ordinary fatigue has one or more of the causes above behind it, it does not stop you doing what you need to do, and it tends to ease as your body adjusts to eating less. The US labels describe the gastrointestinal side effects following that same arc, most noticeable during initiation and escalation and then settling; whether your fatigue follows it is something a dated log will show.

The warnings sections of the same labels describe what ordinary does not look like. Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea and vomiting, is the sign of acute pancreatitis that the Wegovy, Zepbound and Mounjaro labels all instruct prescribers to watch for. Nausea, vomiting or diarrhea that does not go away is the sign the Wegovy Medication Guide asks patients to report right away; in plain terms, being unable to keep fluids down or passing very little urine is the volume depletion that precedes the acute kidney injury reports. Sweating, shakiness, confusion or a fast heartbeat in someone on insulin or a sulfonylurea fits hypoglycemia. Swelling of the face, lips, tongue or throat, trouble breathing or fainting is listed as a serious allergic reaction requiring immediate help. And the Wegovy Medication Guide asks people to tell their provider if their heart feels like it is racing or pounding for several minutes, because the label documents an increase in resting heart rate.

There is a second category that is neither ordinary nor an emergency: fatigue that is heavier than everything else you are feeling, that persists beyond a few weeks with no obvious cause in your log, or that comes with low mood, changes in your sleep that do not resolve, or weakness that makes stairs harder. That kind of tiredness deserves an appointment rather than a wait. It may be nothing more than a larger deficit than you realized, but it may also be something unrelated to the medication that has been unmasked by the weight loss, and only a clinician who can examine you and run tests can tell the difference.

The practical rule: tiredness with a red-flag sign gets a same-day call, or emergency care if the sign is severe; persistent, worsening or out-of-proportion tiredness gets an appointment; tiredness with an obvious cause in your log gets fixed at the cause and reported at the next routine visit. None of it is managed by changing how or when you take your medication on your own; that stays with your prescriber.

"I have been really tired" is a symptom. "I was flattened for two days after each of the last three doses, on the days I ate under a thousand calories and slept under six hours" is a pattern, and a pattern is something a prescriber can act on. The difference is entirely in what you wrote down at the time.

Five things earn their place. Dose day, so that every other entry has an offset from it: fatigue on day one and fatigue on day six are different observations, one near the peak of a weekly medication's exposure and one near the trough. Hours slept, even roughly, because sleep debt is the cause most often overlooked and the easiest to see once it is on the same timeline as everything else. Roughly what you ate and drank, which is the cause most often underestimated; a photo of each plate is enough, and water counts. Weight, weekly rather than daily, because a sudden drop alongside the tiredness is worth pointing at. And a one-line description of the fatigue itself: when it started, how heavy it was, whether it came with anything from the red-flag list.

This is the practical layer where GLP-1 Tracker fits. It is a free iPhone app that keeps logged doses, injection sites, weight, photo-based meal logging with protein shown first, and dated side-effect notes in one timeline, stored on the device. A note that says tired on a given day sits beside the dose that preceded it and the meals around it, so the offset and the intake are visible without any arithmetic. It also draws an educational estimate of medication level between doses, which exists to help you picture the shape of your week and is never a reason to time, skip or change anything.

Then condense. The night before an appointment, turn the log into three or four lines: when the fatigue tends to land relative to the dose, how it tracks with intake, water and sleep, whether anything from the red-flag list ever appeared, and the one question you most want answered. If you take insulin or a sulfonylurea, add your glucose readings to that summary. Bring the full log as backup, hand over the summary, and leave the decisions where they belong.